The Role of Small Bowel Ultrasound in Initiation of Infliximab in Crohn's Disease Patients

Status unconfirmed

Conditions studied: Inflammatory Bowel Disease, Crohn's Disease

In brief

Goal is to prospectively determine if stool calprotectin and change in bowel wall thickness and hyperemia, as seen on small bowel ultrasound, at week 0, 14, and 54 can be used to predict response at week 54 to infliximab in pediatric patients with small bowel Crohn's Disease.

Key facts

Study ID

NCT02330458

Run by

Cedars-Sinai Medical Center

People needed

20

Starts

2014-07-01

Expected to finish

2018-05-01

Last updated by the study team

2017-07-19

Who can join

Age: 6 and older, up to 23. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 6-23 years
• Initiating Infliximab therapy
• Crohns disease involving the distal small bowel +/- proximal colon
• Willingness to undergo SBUS and fecal calprotectin collection prior to starting infliximab and again at week 14 and week 54
• Able to give consent by patient and/or legal guardian

You may not qualify if…

• Ulcerative colitis or non-Crohn's Disease patients
• Lack of small bowel disease
• Patients started on alternative therapy
• Unable or unwilling to provide consent

Where it is running

• Cedars-Sinai Medical Center — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.